CDEK
← All drugs Report issue

endostatin

Trade name: endostar

Recombinant proteinexperimental

Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. It is reported to serve as an anti-angiogenic agent, similar to angiostatin and thrombospondin. — Wikipedia

Clinical trial activity

138 trials · 78 clinical orgs · 0 marketing orgs

Phase 1
16
Phase 2
107
Phase 3
24
Phase 4
9

Earliest trial started Oct 1, 1999 (NCT00004229)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • endostar
  • endostar
  • endostatin
  • endostatin
  • endostatin, n-terminal-mggshhhhh
  • pegylated endostatin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07154069Phase 3Nov 13, 2025Sun Yat-Sen University
NCT06965231Phase 2Jan 1, 2025Fudan University
NCT06747169Phase 2Dec 17, 2024Zunyi Medical College
NCT06618391Phase 2Oct 8, 2024Henan Medical University
NCT06611826Phase 2Sep 30, 2024Chinese Academy of Medical Sciences
NCT06617936Phase 2Aug 27, 2024Shandong University
NCT06562673Phase 1/Phase 2 (Phase 2)Aug 20, 2024Jiao Tong University
NCT06455410Phase 2Jun 18, 2024Sun Yat-Sen University
NCT06301828Phase 2Feb 21, 2024Nanjing Medical University
NCT06279754Phase 2Feb 18, 2024Xinxiang Medical University
NCT06059261Phase 2Oct 1, 2023Chongqing Medical University
NCT06055816Phase 2Sep 28, 2023Chinese Academy of Medical Sciences, Zhejiang University
NCT06041724Phase 2Sep 18, 2023Fudan University
NCT06047860Phase 2Jun 16, 2023Soochow University
NCT05529355Phase 2Sep 18, 2022Anhui Medical University
NCT05551247Phase 2Sep 15, 2022Jiao Tong University
NCT05514275Phase 2Aug 1, 2022Chinese Academy of Medical Sciences, Zhejiang University
NCT05448781Phase 2Jul 20, 2022Guangzhou Medical University
NCT05278715Phase 2Apr 13, 2022Capital Medical University
NCT05298020Phase 2Apr 1, 2022Xuzhou Medical University
Showing 20 of 138 trials
Page 1 / 7

Organizations

Research & Development (78)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Simcere Pharmaceutical Co., LtdFor profit271742007
Chinese Academy of Medical SciencesAcademic/Hospital171132007
People's Liberation Army of ChinaGovernment14742008
Fudan UniversityAcademic/Hospital131222007
Sun Yat-Sen UniversityAcademic/Hospital13932005
Zhejiang UniversityAcademic/Hospital11732009
Jiao Tong UniversityAcademic/Hospital9732007
Nanjing Medical UniversityAcademic/Hospital9642009
Peking UniversityAcademic/Hospital7442008
Capital Medical UniversityAcademic/Hospital6522007
Guangxi Medical UniversityAcademic/Hospital6332009
Guangzhou Medical UniversityAcademic/Hospital5312009
Hacettepe UniversityAcademic/Hospital5222014
Protgen LtdFor profit5522009
Tianjin Medical UniversityAcademic/Hospital5042008
Fujian Medical UniversityAcademic/Hospital4122009
Shandong UniversityAcademic/Hospital4212012
The First People's Hospital of LianyungangAcademic/Hospital4112011
Anhui Medical UniversityAcademic/Hospital3232016
Central South UniversityAcademic/Hospital3112011
78 organizations
Page 1 / 4